X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (501) 501
Publication (59) 59
Patent (14) 14
Book Chapter (9) 9
Book Review (8) 8
Book / eBook (5) 5
Conference Proceeding (3) 3
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (293) 293
female (170) 170
middle aged (168) 168
male (164) 164
oncology (158) 158
aged (149) 149
index medicus (135) 135
adult (130) 130
hematology (130) 130
antineoplastic combined chemotherapy protocols - therapeutic use (97) 97
aged, 80 and over (92) 92
treatment outcome (92) 92
rituximab (91) 91
non-hodgkins-lymphoma (88) 88
prognosis (82) 82
chemotherapy (75) 75
cancer (69) 69
lymphomas (64) 64
disease-free survival (56) 56
survival analysis (50) 50
b-cell lymphoma (49) 49
lymphoma, large b-cell, diffuse - drug therapy (49) 49
antineoplastic agents - therapeutic use (47) 47
cyclophosphamide - administration & dosage (46) 46
life sciences (45) 45
lymphoma (45) 45
doxorubicin - administration & dosage (44) 44
antibodies, monoclonal, murine-derived (41) 41
antibodies, monoclonal - therapeutic use (40) 40
antineoplastic combined chemotherapy protocols - administration & dosage (39) 39
therapy (39) 39
prednisone - administration & dosage (37) 37
lymphoma, non-hodgkin - drug therapy (36) 36
retrospective studies (36) 36
recurrence (34) 34
vincristine - administration & dosage (34) 34
survival rate (33) 33
care and treatment (32) 32
elderly-patients (31) 31
follicular lymphoma (30) 30
neoplasm staging (30) 30
survival (30) 30
adolescent (29) 29
drug administration schedule (29) 29
drug therapy (28) 28
follow-up studies (28) 28
hematology, oncology and palliative medicine (27) 27
trial (27) 27
time factors (26) 26
antineoplastic combined chemotherapy protocols - adverse effects (25) 25
combined modality therapy (25) 25
remission induction (25) 25
research (25) 25
antibodies, monoclonal - administration & dosage (23) 23
hemic and lymphatic diseases (23) 23
leukemia (22) 22
lymphoma, b-cell - drug therapy (22) 22
lymphoma, large b-cell, diffuse - mortality (22) 22
[ sdv.can ] life sciences [q-bio]/cancer (21) 21
chronic lymphocytic-leukemia (21) 21
doxorubicin - therapeutic use (21) 21
expression (21) 21
prospective studies (21) 21
risk factors (21) 21
transplantation (21) 21
young adult (21) 21
abridged index medicus (20) 20
cyclophosphamide - therapeutic use (20) 20
disease progression (20) 20
phase-ii (20) 20
clinical trials (19) 19
lymphoma, non-hodgkin - mortality (19) 19
non-hodgkin's lymphomas (19) 19
prednisone - therapeutic use (19) 19
vincristine - therapeutic use (19) 19
age factors (18) 18
antineoplastic agents - adverse effects (18) 18
chop (18) 18
doxorubicin (18) 18
kaplan-meier estimate (18) 18
non-hodgkin's lymphoma (18) 18
antibodies, monoclonal, murine-derived - therapeutic use (17) 17
cyclophosphamide (17) 17
health aspects (17) 17
lymphoma, follicular - drug therapy (17) 17
medicine, general & internal (17) 17
salvage therapy (17) 17
vincristine (17) 17
anti-cd20 monoclonal-antibody (16) 16
clinical trials as topic (16) 16
diagnosis (16) 16
disease (16) 16
lymphoma - drug therapy (16) 16
lymphoma, follicular - pathology (16) 16
monoclonal antibodies (16) 16
antineoplastic agents - administration & dosage (15) 15
diffuse large b-cell lymphoma (15) 15
dose-response relationship, drug (15) 15
antibodies, monoclonal, murine-derived - administration & dosage (14) 14
classification (14) 14
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (520) 520
French (15) 15
Finnish (2) 2
Swedish (2) 2
German (1) 1
Norwegian (1) 1
Polish (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
2013, Current clinical oncology, ISBN 9781627034081, Volume 43
Web Resource
The Lancet Oncology, ISSN 1470-2045, 01/2014, Volume 15, Issue 1, pp. 7 - 8
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Journal Article
Expert Review of Clinical Pharmacology, ISSN 1751-2433, 09/2017, Volume 10, Issue 9, pp. 923 - 933
Introduction: Rituximab, an anti-CD20 monoclonal antibody, is a key therapeutic in the treatment of B cell lymphomas and rheumatoid arthritis (RA). Global... 
chronic lymphocytic leukemia | safety | CT-P10 | non-Hodgkin’s lymphoma | rheumatoid arthritis | Biosimilar | efficacy | rituximab | RHEUMATOID-ARTHRITIS | DIAGNOSIS | INFLIXIMAB CT-P13 | LESSONS | CANCER | CLINICAL-PRACTICE GUIDELINES | PF-05280586 | TRIAL | IMPACT | non-Hodgkin's lymphoma | PHARMACOLOGY & PHARMACY
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 297 - 311
Journal Article
Future oncology (London, England), 05/2017, Volume 13, Issue 15s, p. 1
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 460 - 468
Summary Background Diffuse large B-cell lymphoma is a common cancer in elderly patients. Although treatment has been standardised in younger patients, no... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE RITUXIMAB | COLONY-STIMULATING FACTOR | PROGNOSTIC-FACTORS | RESPONSE CRITERIA | ONCOLOGY | AGGRESSIVE LYMPHOMAS | MALIGNANT-LYMPHOMAS | NON-HODGKINS-LYMPHOMA | COMPREHENSIVE GERIATRIC ASSESSMENT | DETUDE-DES-LYMPHOMES | CHOP CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Female | France | Odds Ratio | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Risk Factors | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Analysis of Variance | Belgium | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - adverse effects | Doxorubicin - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Oncology, Experimental | Aged patients | Product development | Prednisone | Lymphomas | Research | Cancer | Toxicity | Albumin | Clinical trials | Multivariate analysis | Doxorubicin | Survival | Vincristine | Side effects | Motivation | Age | rituximab | B-cell lymphoma | Geriatrics | Neutropenia
Journal Article
ONCOLOGY (United States), ISSN 0890-9091, 2013, Volume 27, Issue 2, pp. 146 - 148
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials | Life Sciences
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2016, Volume 22, Issue 12, pp. 2919 - 2928
Journal Article